Virometix inks Series B
Virometix, a developer of vaccines and immunotherapeutic drugs for the prevention and treatment of infectious and oncology diseases, has raised CHF 7.5 million in Series B financing.
Virometix, a developer of vaccines and immunotherapeutic drugs for the prevention and treatment of infectious and oncology diseases, has raised CHF 7.5 million in Series B financing.
Copyright PEI Media
Not for publication, email or dissemination